AIM Vaccin

AIM Vaccine is a leading full-industrial chain vaccine company in China, specializing in the research, development, manufacturing, and commercialization of high-quality vaccines. The company operates five distinct technology platforms, including mRNA, recombinant protein, and viral vector technologies, supporting a robust pipeline of over 20 candidates. AIM Vaccine is currently the largest private vaccine enterprise in China by sales volume, with a dominant market position in rabies and hepatitis B vaccines. Their strategic focus involves advancing next-generation vaccines for COVID-19, HPV, and pneumococcal diseases to address significant unmet medical needs globally. The company is listed on the Hong Kong Stock Exchange and maintains multiple GMP-certified manufacturing facilities across China. With a strong emphasis on innovation, AIM Vaccine was among the first in China to advance an mRNA-based vaccine into late-stage clinical trials.